GLP-1 patch
You are getting oriented.
Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.
No FDA-approved transdermal patch delivers semaglutide, tirzepatide or any other GLP-1 receptor agonist. This is not a gap in the market waiting to be filled by a better product — it reflects what these molecules are. They are peptides, and peptides are large, fragile and poorly absorbed through intact skin. That is also why the injectable route dominates and why the one oral product needs an absorption enhancer and a fasting requirement to work at all.
Every approved route for a GLP-1 receptor agonist
The complete list. Anything not on it is not an approved GLP-1 medication.
- Subcutaneous injectionSemaglutide, tirzepatide, liraglutide, dulaglutide and exenatide are all administered this way, weekly or daily depending on the product.
- Oral tabletSemaglutide only, as Rybelsus. It is the sole approved GLP-1 receptor agonist that is not injected.
There is no approved transdermal patch, sublingual drop, capsule sold over the counter, or topical preparation delivering any GLP-1 receptor agonist. Two routes is the whole list.
So products sold as GLP-1 patches are not approved GLP-1 medications, whatever the packaging implies. They generally sit in a different regulatory category — supplement or cosmetic — with different requirements and no prescribing information. That is checkable in about thirty seconds, and the three questions below work on any brand, including ones that do not exist yet.
Three questions that settle it for any brand
New products appear constantly. These work on all of them.
- 1. Does it require a prescription?Every approved GLP-1 receptor agonist does. If you can add it to a cart without one, it is not one of them. This single question settles most cases.
- 2. Is there prescribing information?Approved drugs have a label on DailyMed listing dosing, contraindications and adverse reaction rates. Supplements do not have one, because they were never required to produce it.
- 3. Does the claim carry the supplement disclaimer?The sentence about not being intended to diagnose, treat, cure or prevent disease is required on supplement structure/function claims. Its presence tells you which regulatory path the product is on.
Two different regulatory paths
Which one a product travelled determines what had to be proved before it could be sold.
- Prescription drug
- FDA reviews safety and efficacy before it can be sold. Carries prescribing information with dosing, contraindications and adverse-reaction rates. Every medication on this site.
- Dietary supplement
- No FDA approval before sale. The manufacturer is responsible for its own safety substantiation, and structure/function claims carry a disclaimer stating the product is not intended to diagnose, treat, cure or prevent disease. Products sold as GLP-1 "support", "booster" or "daily".
This is a description of two legal pathways, not a judgement about any product. A supplement being on the supplement path is not a criticism of it — it is the reason the two categories cannot be compared on a price-per-month basis the way two prescription options can.
Common questions
- Why can a peptide not cross skin?
- Molecular size and stability are the practical barriers. Transdermal delivery favours small, lipophilic molecules; therapeutic peptides are neither, which is why the approved products are injected or, in one case, taken orally with a specific absorption strategy.
- What about patches that say they boost your own GLP-1?
- That is a different claim from delivering a GLP-1 receptor agonist, and it places the product on the supplement path where no pre-market efficacy review is required. Reading which of the two claims is being made usually settles what you are looking at.
- Could an approved patch exist later?
- Possibly. If one is approved it will have prescribing information on DailyMed and require a prescription, which is exactly what the checklist above tests for. Until then the absence of those is the answer.
Side-by-side
Structural facts from each product’s prescribing information.
| Product | Active ingredient | Indication | Frequency | Start | Max labelled | Steps to max |
|---|---|---|---|---|---|---|
| Zepbound Eli Lilly | Tirzepatide | Weight management | Weekly | 2.5 mg | 15 mg | 6 |
| Mounjaro Eli Lilly | Tirzepatide | Type 2 diabetes | Weekly | 2.5 mg | 15 mg | 6 |
| Wegovy Novo Nordisk | Semaglutide | Weight management | Weekly | 0.25 mg | 2.4 mg | 5 |
| Wegovy tablets Novo Nordisk | Semaglutide (oral) | Weight management | Daily | 1.5 mg | 25 mg | 4 |
| Ozempic Novo Nordisk | Semaglutide | Type 2 diabetes | Weekly | 0.25 mg | 2 mg | 4 |
| Rybelsus Novo Nordisk | Semaglutide (oral) | Type 2 diabetes | Daily | 3 mg | 14 mg | 3 |
| Saxenda Novo Nordisk | Liraglutide | Weight management | Daily | 0.6 mg | 3 mg | 5 |
| Trulicity Eli Lilly | Dulaglutide | Type 2 diabetes | Weekly | 0.75 mg | 4.5 mg | 4 |
Sources and last review
Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- Zepbound (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Mounjaro (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Wegovy (Semaglutide) prescribing information — Novo Nordisk, label revised 30 June 2026, checked 7 August 2026
- Ozempic (Semaglutide) prescribing information — Novo Nordisk, label revised 10 June 2026, checked 7 August 2026
- Rybelsus (Semaglutide) prescribing information — Novo Nordisk, label revised 20 May 2026, checked 7 August 2026
- Saxenda (Liraglutide) prescribing information — Novo Nordisk, label revised 15 June 2026, checked 7 August 2026
- Trulicity (Dulaglutide) prescribing information — Eli Lilly, label revised 25 March 2026, checked 7 August 2026
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.